ClinicalTrials.gg
CompletedNCT02281591Updated Apr 8, 2025Results posted

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

A Phase 1 interventional study of BIA 2-093 and S-licarbazepine in Epilepsy, sponsored by Bial - Portela C S.A.. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing eslicarbazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. eslicarbazepine · Epilepsy.

Enrollment
22nd of 45
32 · median 32
Started
2006
with 2 others
Phase 1
29 of 45
none open now
Registered
28th of 45
by date
Lead sponsor
40 of 45
Bial - Portela C S.A.

Among the 45 studies testing eslicarbazepine in Epilepsy, this one is the 22nd largest by enrollment, is one of 3 that started in 2006, is one of 29 in phase 1, and was the 28th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 45 studies testing eslicarbazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About eslicarbazepine

eslicarbazepine: first FDA approval 2013 (APTIOM), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing eslicarbazepine in Epilepsy as a file.
02

Study summary

Single centre, open-label, randomised study in four parallel groups of healthy volunteers

Read the detailed description

Single centre, open-label, randomised study in four parallel groups of healthy volunteers: Group 1 = 900 mg of eslicarbazepine acetate (ESL, BIA 2-093); Group 2 = 450 mg of S-licarbazepine plus 450 mg of R-licarbazepine; Group 3 = 450 mg of S-licarbazepine; Group 4 = 450 mg of Rlicarbazepine. In each group, the study consisted of a single-dose period (Phase A) followed by a repeateddose period of 7 days of duration in which the investigational product was administered once daily (Phase B). The repeated-dose phase started 96 h post single-dose.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged between 18 and 45 years, inclusive.
  • Subjects of (BMI) between 19 and 30 kg/m2, inclusive.
  • Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, neurological examination, and 12-lead .
  • Subjects who had clinical laboratory tests clinically acceptable at screening and admission.
  • Subjects who had negative tests for , anti- Ab and -1 and HIV-2 Ab at screening.
  • Subjects who were negative for drugs of abuse and alcohol at screening and admission.
  • Subjects who were non-smokers or who smoke \< 10 cigarettes or equivalent per day.
  • Subjects who are able and willing to give written .
  • (If female) She was not of by reason of surgery or, if of childbearing potential, she used one of the following methods of : double barrier, intrauterine device or abstinence.
  • (If female) She had a negative pregnancy test at screening and admission to Phase A.

Exclusion criteria

Exclusion Criteria:

  • Subjects who did not conform to the above inclusion criteria, OR
  • Subjects who had a history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
  • Subjects who had a clinically relevant surgical history.
  • Subjects who had a clinically relevant family history.
  • Subjects who had a history of relevant atopy.
  • Subjects who had a history of relevant drug (especially carbamazepine or oxcarbazepine).
  • Subjects who had a history of alcoholism or drug abuse.
  • Subjects who consumed more than 14 units of alcohol a week.
  • Subjects who had a significant infection or known inflammatory process on screening or admission.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    eslicarbazepine acetate

    900mg of eslicarbazepine acetate (ESL, BIA 2-093)

    Drug: BIA 2-093

  • Active comparator
    S-licarbazepine R-licarbazepine

    450 mg of S-licarbazepine plus 450 mg of R-licarbazepine

    Drug: S-licarbazepine · Drug: R-licarbazepine

  • Active comparator
    S-licarbazepine

    450 mg of S-licarbazepine

    Drug: S-licarbazepine

  • Active comparator
    R-licarbazepine

    450 mg of Rlicarbazepine

    Drug: R-licarbazepine

Interventions

  • Tablets containing 900 mg

  • capsules containing 225 mg

  • DrugR-licarbazepine

    capsules containing 225 mg

06

What researchers measure

Primary outcomes

  1. Cmax - the Maximum Plasma Concentration

    BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

    Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.

  2. Tmax - the Time of Occurrence of Cmax

    BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

    Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.

  3. AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity

    BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

    Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.

Secondary outcomes

  1. AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point

    BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

    Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.

07

Results

Posted Dec 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
Started8888
Completed8888
Not completed0000

Outcome measures

PrimaryCmax - the Maximum Plasma Concentration

BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

Time frame:
Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
Reported as:
Mean · ng/mL
Cmax - the Maximum Plasma Concentration
ng/mLEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
Cmax (BIA 2-194)15809 ± 318310496 ± 143210364 ± 3352437 ± 143
Cmax (BIA 2-195)222 ± 68.48099 ± 1258132 ± 29.66941 ± 1054
Cmax (Oxcarbazepine)136 ± 25.1261 ± 53.592.8 ± 21.8101 ± 28.6
PrimaryTmax - the Time of Occurrence of Cmax

BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

Time frame:
Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
Reported as:
Mean · hours
Tmax - the Time of Occurrence of Cmax
hoursEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
tmax (BIA 2-194)1.99 ± 0.9161.01 ± 0.3200.965 ± 0.49610.7 ± 3.69
tmax (BIA 2-195)18.6 ± 4.141.41 ± 0.32011.7 ± 3.771.22 ± 0.582
tmax (Oxcarbazepine)3.59 ± 1.611.34 ± 0.3541.36 ± 1.441.21 ± 0.641
PrimaryAUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity

BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

Time frame:
Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
Reported as:
Mean · ng.h/mL
AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity
ng.h/mLEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
AUC0-∞ (BIA 2-194)271191 ± 47416201409 ± 37377132724 ± 2017511003 ± 4476
AUC0-∞ (BIA 2-195)8816 ± 2168116884 ± 224255417 ± 82466087 ± 16072
AUC0-∞ (Oxcarbazepine)3181 ± 10784726 ± 11632500 ± 19231073 ± 793
SecondaryAUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point

BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.

Time frame:
Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
Reported as:
Mean · ng.h/mL
AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
ng.h/mLEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
AUC0-t (BIA 2-194)268045 ± 46861198313 ± 38771130147 ± 193269419 ± 4707
AUC0-t (BIA 2-195)6757 ± 2211114635 ± 217413074 ± 100165203 ± 16161
AUC0-t (Oxcarbazepine)1947 ± 7573401 ± 902748 ± 308422 ± 247

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eslicarbazepine Acetate—0/8 (0%)6/8 (75%)
S-licarbazepine R-licarbazepine—0/8 (0%)8/8 (100%)
S-licarbazepine—0/8 (0%)4/8 (50%)
R-licarbazepine—0/8 (0%)5/8 (62.5%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventEslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepine
TirednessGeneral disorders1/86/81/82/8
HeadacheNervous system disorders3/83/81/81/8
Paraesthesia lipsGastrointestinal disorders0/82/81/80/8
DizzinessNervous system disorders2/80/80/80/8
Burning sensation in eyeEye disorders1/80/80/80/8
Visual disturbanceEye disorders0/80/80/81/8
Dry mouthGastrointestinal disorders1/80/80/80/8
NauseaGastrointestinal disorders1/80/80/80/8
Numbness of tongueGastrointestinal disorders0/81/80/80/8
Oral drynessGastrointestinal disorders0/81/80/81/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Eslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepineTotal
<=18 years00000
Between 18 and 65 years888832
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Eslicarbazepine AcetateS-licarbazepine R-licarbazepineS-licarbazepineR-licarbazepineTotal
Female444416
Male444416
08

Study locations

1 site
  • Scope International Life Sciences AG,
    Hamburg, D-22525, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 8 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 2, 2014
Start
Jun 2006
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Results first posted
Dec 3, 2014
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02281591
Responsible party
Sponsor
First posted
Nov 2, 2014
Start date
Jun 2006
Primary completion
Jul 2006
Completion
Jul 2006
Results posted
Dec 3, 2014
Last update
Apr 8, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eslicarbazepine

Start the discussion